128851-36-5 Usage
Chemical structure
A sulfonamide derivative with an imidazolidine-2,4-dione core and a brominated benzofuran group.
Potential biological activities
The compound may exhibit biological activities due to its unique chemical structure.
Applications
It may have applications in the field of medicinal chemistry as a potential drug candidate.
Structural features
The presence of a brominated benzofuran group and a sulfonamide group contribute to its potential pharmacological properties.
Further research
More research is needed to explore its potential therapeutic uses and to understand its mechanisms of action in biological systems.
Pharmacological properties
The compound's pharmacological properties are not yet fully understood and require further investigation.
Synthesis
The synthesis of 1-[(3-bromo-1-benzofuran-2-yl)sulfonyl]imidazolidine-2,4-dione involves the formation of the imidazolidine-2,4-dione core and the subsequent introduction of the brominated benzofuran group.
Stability
The stability of the compound under various conditions, such as temperature, pH, and in the presence of enzymes, needs to be evaluated.
Toxicity
The toxicity profile of 1-[(3-bromo-1-benzofuran-2-yl)sulfonyl]imidazolidine-2,4-dione should be assessed to determine its safety for potential therapeutic use.
Drug resistance
The compound's potential to overcome drug resistance in various diseases, such as cancer or bacterial infections, should be investigated.
Check Digit Verification of cas no
The CAS Registry Mumber 128851-36-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,8,8,5 and 1 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 128851-36:
(8*1)+(7*2)+(6*8)+(5*8)+(4*5)+(3*1)+(2*3)+(1*6)=145
145 % 10 = 5
So 128851-36-5 is a valid CAS Registry Number.
128851-36-5Relevant articles and documents
Hydantoin derivatives
-
, (2008/06/13)
The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives. The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton. The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.
